Not getting to goal: the clinical costs of noncompliance.
BACKGROUND
Cardiovascular disease is characterized by significant prevalence and cost in the managed care setting. Despite overwhelming evidence in favor of statin use for lowering low-density lipoprotein cholesterol (LDL-C), medication compliance to these agents remains suboptimal, as it does in other disease states.


OBJECTIVE
To establish the benefits of statin therapy in cardiovascular disease, demonstrate the current lack of compliance to lipid-lowering agents, and present potential interventions to improve medication compliance.


CONCLUSIONS
As evidenced by a consistent body of clinical trial data, intensive LDL-C reduction plays a critical role in the mitigation of cardiovascular risk. Yet, the effectiveness of lipid-lowering strategies is offset to a significant degree by both physician and patient factors that limit goal attainment. Despite extensive evidence demonstrating the benefits of lipid-lowering therapy, many patients are still not getting to goal because the transition from physician awareness to clinical practice is lagging. Patient noncompliance to therapy also limits goal attainment, thus resulting in poor health outcomes and increasing managed care costs.


CONCLUSIONS
To overcome the issues surrounding LDL-C goal attainment, interventions designed to increase goal attainment should be based not only on the conclusions of clinical trials but also on successful patientand provider-focused behavioral strategies. Interventions for improving adherence to lipid-lowering medication will provide an opportunity to decrease morbidity, mortality, and hospitalization associated with cardiovascular disease.
Ansell
Benjamin J
BJ
The David Geffen School of Medicine at UCLA, UCLA School of Medicine, 100 UCLA Medical Plaza, Suite 525, Los Angeles, CA 90095, USA. bansell@mednet.ucla.edu
D002318:Cardiovascular Diseases / Q000097:blood / Q000188:drug therapy*; D008078:Cholesterol, LDL / Q000097:blood*; D002986:Clinical Trials as Topic / Q000191:economics; D004305:Dose-Response Relationship, Drug; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D015141:Los Angeles; D054539:Medication Therapy Management / Q000191:economics / Q000458:organization & administration; D009937:Organizational Objectives; D018570:Risk Assessment / Q000191:economics / Q000379:methods; D012307:Risk Factors; D016896:Treatment Outcome; D016903:Drug Monitoring
D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors